Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Locally Advanced Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Pegfilgrastim|DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel
Sponsor: Icahn School of Medicine at Mount Sinai